Analisis Efektivitas Biaya Terapi Inhalasi Pada Pasien Asma Rawat Inap Rsud Dr. Moewardi Tahun 2017

Wardani, Sisca Dwi Kusuma and -, Mariska Sri Harlianti, M.Sc., Apt (2019) Analisis Efektivitas Biaya Terapi Inhalasi Pada Pasien Asma Rawat Inap Rsud Dr. Moewardi Tahun 2017. Skripsi thesis, Universitas Muhammadiyah Surakarta.

[img] PDF (Surat Pernyataan Publikasi)
Surat Pernyataan Publikasi.pdf
Restricted to Repository staff only

Download (704kB) | Request a copy
[img] PDF (Naskah Publikasi)
upload perpus_Naskah Publikasi_Sisca Dwi Kusuma W_K100150136.pdf

Download (1MB)


Asthma is one of the top 5 causes of death in the world. Based on the results of the Riskesdas 2013, the prevalence of inpatient diseases reached 25.66% while the prevalence of outpatients was 24.05%. Inhaled corticosteroids are used to control asthma symptoms so they must be used routinely. Based on this, it is necessary to analyze the therapy of asthma to obtaincost effectiveness. This study discusses corticosteroid use and analysis of cost analysis in hospitalized asthma patients at RSUD Dr. Moewardi in 2017. The type of research from this study is non-experimental (observational). Data retrieval was done retrospectively, where a sample of 15 patients was obtained. The cost analysis method used is ACER, by calculating direct medical costs, calculating medical expenses based on 1 year results, namely patients not returning to the hospital (outpatient care, hospitalization, emergency unit) because asthma relapsed or could not be used. The most cost-effective therapy inhaled are based on ACER values in Berotec class III: Atrovent: Pulmicort for Rp 13,842.46, in class I Seretide: Berotec: Atrovent for Rp 33,132.95, and in the V-VIP class the most cost-effective is Combivent use : Pulmicort with ACER for Rp. 34,578.

Item Type: Karya ilmiah (Skripsi)
Uncontrolled Keywords: asthma, ACER, cost effectiveness analysis, inhaled therapy.
Subjects: R Medicine > RS Pharmacy and materia medica
Divisions: Fakultas Farmasi > Farmasi
Date Deposited: 14 Feb 2019 03:25
Last Modified: 14 Feb 2019 03:25

Actions (login required)

View Item View Item